

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Electrochemical microfluidic immunosensor based on TES-AuNPs@Fe₃O₄ and**
2 **CMK-8 for IgG anti-*Toxocara canis* determination**

3
4 Claudio F. Jofre^a, Matías Regiart^b, Martin A. Fernández-Baldo^a, Mauro Bertotti^b,
5 Julio Raba^a, Germán A. Messina^{a,*}

6
7 ^a *INQUISAL. Department of Chemistry, National University of San Luis. CONICET.*
8 *Chacabuco 917. D5700BWS. San Luis, Argentina.*

9 ^b *Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo,*
10 *Av. Prof. Lineu Prestes, 748, 05508-000 São Paulo, SP, Brazil.*

11
12
13
14
15
16
17
18
19
20 Authors to whom correspondence should be addressed: *Germán A. Messina
21 (messina@unsl.edu.ar) (Tel.) +54 266 442 5385; (Fax) +54 266 443 0224. INQUISAL.
22 Departamento de Química, Universidad Nacional de San Luis. CONICET. Chacabuco 917.
23 D5700BWS. San Luis, Argentina.

1
2
3
4 **25 Abstract**

5
6 **26** We report a microfluidic immunosensor for the electrochemical determination of
7
8
9 **27** IgG antibodies anti-*Toxocara canis* (IgG anti-*T. canis*). In order to improve the selectivity
10
11 **28** and sensitivity of the sensor, core-shell gold-ferric oxide nanoparticles (AuNPs@Fe₃O₄),
12
13
14 **29** and ordered mesoporous carbon (CMK-8) in chitosan (CH) were used. IgG anti-*T. canis*
15
16 **30** antibodies detection was carried out using a non-competitive immunoassay, in which
17
18
19 **31** excretory secretory antigens from *T. canis* second-stage larvae (TES) were covalently
20
21 **32** immobilized on AuNPs@Fe₃O₄. CMK-8-CH and AuNPs@Fe₃O₄ were characterized by
22
23
24 **33** transmission electron microscopy, scanning electron microscopy, energy dispersive
25
26 **34** spectrometry, cyclic voltammetry, electrochemical impedance spectroscopy, and N₂
27
28
29 **35** adsorption-desorption isotherms.

30
31 **36** Antibodies present in serum samples immunologically reacted with TES, and then
32
33
34 **37** were quantified by using a second antibody labeled with horseradish peroxidase (HRP-anti-
35
36 **38** IgG). HRP catalyzes the reduction from H₂O₂ to H₂O with the subsequent oxidation of
37
38
39 **39** catechol (H₂Q) to p-benzoquinone (Q). The enzymatic product was detected
40
41 **40** electrochemically at -100 mV on a modified sputtered gold electrode. The detection limit
42
43 **41** was 0.10 ng mL⁻¹, and the coefficients of intra- and inter-assay variation were less than 6
44
45
46 **42** %, with a total assay time of 20 min. As can be seen, the electrochemical immunosensor is
47
48 **43** a useful tool for in situ IgG antibodies anti-*T. canis* determination.

49
50
51 **44**
52
53 **45**
54
55 **46 Keywords:** *Toxocara canis*; Toxocariosis; AuNPs@Fe₃O₄; Microfluidic immunosensor;
56
57
58 **47** Electrochemical.
59
60 **48**

1
2
3
4 **49 1. Introduction**

5
6 50 Toxocariosis is a disease caused by *Toxocara canis* and less commonly by
7
8
9 51 *Toxocara cati*, which are global prolific nematodes with a complex life cycle [1]. The
10
11 52 infection in humans is acquired by oral route through accidental ingestion of infective eggs
12
13
14 53 from soil-contaminated hands, consumption of poorly sanitized vegetables, and uncooked
15
16 54 meats [2, 3]. *Toxocara* eggs hatch in the intestine and release larvae into the lumen, where
17
18
19 55 they can penetrate the intestine, reach the circulation and then spread by the systemic route.
20
21 56 The larvae migrate throughout the body but cannot mature, and instead encyst as second-
22
23
24 57 stage larvae [4]. The inflammatory process, caused by the larvae stage, is attributed to small
25
26 58 amounts of secretion and excretion products (lectins, mucins, enzymes), which interact and
27
28
29 59 modulate the host immune response [5]. In brief, clinical manifestations of toxocariosis are
30
31 60 related to the larval migration and the host immune response. The clinical forms of
32
33
34 61 toxocariosis are systemic (visceral larva migrans), localized (ocular and neurological), and
35
36 62 asymptomatic [6].

37
38 63 Human toxocariosis is diagnosed by clinical manifestations, ophthalmology (OLM),
39
40
41 64 clinical pathology, including eosinophilia, bioimaging, and serology. In cases of OLM,
42
43
44 65 extirpation by biopsy and subsequent histopathology can be performed and parasite
45
46 66 material can be speciated by PCR. Moreover, serological methods using immunological
47
48
49 67 techniques are recognized as the most effective approach to the laboratory diagnosis of
50
51 68 human toxocariosis [7]. In this context, detection of IgG antibodies to *T. canis* by methods
52
53
54 69 as enzyme-linked immunosorbent assay (ELISA) using excretory-secretory antigens from
55
56 70 *T. canis* second stage larvae (TES) is the most widely used [8, 9].

57
58 71 In recent years, immunosensors promise to be the solution to the immunodiagnostic
59
60 72 of various parasitic diseases [10-15]. In addition, microfluidic immunosensors with
61
62
63
64
65

1
2
3
4 73 electrochemical detection represent an attractive strategy due to their advantages, such as
5
6 74 the high degree of integration, low consumption of reagents and samples, and low detection
7
8
9 75 limit [16-18]. These devices are considered to be valuable and promising due to their
10
11 76 robustness, simplicity, sensitivity, ease of handling, cost-effectiveness, rapid analysis and
12
13
14 77 miniaturization ability [19, 20]. Furthermore, microfluidic immunosensors modified with
15
16 78 nanoparticles possess higher selectivity than naked sensors, and have higher sensitivity
17
18
19 79 because of the increased surface area provided by the nanoparticles [21-24]. Recently, the
20
21 80 synthesis of magnetic nanoparticles increased, and they were applied in numerous scientific
22
23
24 81 fields such as proteins purification, biological separations, target delivery, magnetic
25
26 82 resonance imaging, therapy, and biosensors fabrication [25-27]. In addition, much interest
27
28
29 83 has been deposited in the incorporation of magnetic nanomaterials to other functional
30
31 84 platforms or nanostructures. The exceptional applicability properties are the advantages of
32
33
34 85 the new structures [28]. Among these, the iron-gold core-shell structure has drawn attention
35
36 86 due to the apparent benefits of gold nanoparticles (AuNPs). Gold is an inert element, very
37
38
39 87 useful as a coating material for protecting magnetic nanoparticles, due to the high
40
41 88 versatility in surface modification processes, great catalytic properties, and unique
42
43
44 89 biocompatibility [29, 30]. Up till now, gold-ferric oxide core/shell nanoparticles
45
46 90 (AuNPs@Fe₃O₄) have been considered as excellent candidates to be used as biomolecules
47
48
49 91 immobilization platform, for capture and recognition elements (antigens, antibodies,
50
51 92 enzymes or DNA) in microfluidic immunosensors, because of their simple synthesis,
52
53 93 excellent biocompatibility and large surface area [31].

54
55 94 Another strategy to be employed in the microfluidic immunosensor design is the
56
57
58 95 modification of the working electrode surface with different materials, such as ordered
59
60 96 mesoporous carbons (OMCs) [32]. OMCs like CMK-8 have been used for electrode
61
62
63
64
65

1
2
3
4 97 modification because of their excellent electrical conductivity, high surface area, chemical
5
6 98 and thermal stability, and their facile functionalization [33-36].
7
8

9 99 In the present work, we developed an electrochemical microfluidic immunosensor
10
11 100 for the toxocariosis diagnosis based on the use of core-shell AuNPs@Fe₃O₄ for covalent
12
13
14 101 immobilization of TES antigen, and the working electrode modification with CMK-8 in
15
16 102 chitosan (CH). IgG anti-*T. canis* antibodies present in the serum samples were detected by
17
18 103 using a non-competitive immunoassay into the microfluidic device. To the best of our
19
20
21 104 knowledge, this is the first electrochemical microfluidic immunosensor reported for the IgG
22
23 105 anti-*T. canis* antibodies detection based on magnetic core-shell nanoparticles and ordered
24
25
26 106 mesoporous carbon materials.
27

28 29 30 31 108 **2. Experimental**

32 33 109 **2.1. Materials and reagents**

34
35
36 110 All reagents used were of analytical reagent grade. Triblock copolymer P123,
37
38 111 tetraethyl orthosilicate (TEOS 98%), CH (from crab shells, medium molecular, 85%
39
40 112 deacetylated), FeCl₂, FeCl₃, [Fe(CN)₆]^{3-/4-}, HAuCl₄, 3-mercaptopropionic acid (MPA),
41
42
43 113 Bovine serum albumin (BSA), 4-tert-butylcatechol (4-TBC) N-(3-dimethylaminopropyl)-
44
45 114 N-ethylcarbodiimide (ECD), and N-hydroxysuccinimide (NHS) were acquired from Sigma-
46
47
48 115 Aldrich, St. Louis, USA. Disodium phosphate (Na₂HPO₄), monosodium phosphate
49
50 116 (NaH₂PO₄), trisodium citrate dehydrate, potassium chloride (KCl), and ethanol were
51
52
53 117 purchased from Merck (Darmstadt, Germany). SU-8 photoresist, Sylgard 184, including
54
55 118 PDMS prepolymer and curing agent were obtained from Clariant Corporation
56
57
58 119 (Sommerville, NJ, USA) and Dow Corning (Midland, MI, USA), respectively. The enzyme
59
60 120 immunoassay for the qualitative determination of IgG antibodies against *Toxocara canis* in
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

121 human serum (RIDASCREEN® Toxocara IgG test) was purchased from R-Biopharm AG
122 (Darmstadt, Germany), and used according to the manufacturer's instructions. Anti-human
123 γ -chain was purchased from Abcam (USA). All the other employed reagents were of
124 analytical grade and were used without further purification. Aqueous solutions were
125 prepared by using purified water from a Milli-Q system.

126

127 **2.2. Apparatus**

128 Amperometric and voltammetric experiments were performed with a BAS LC-4C
129 Electrochemical Detector, and a BAS 100 B/W Electrochemical Workstation (Bioanalytical
130 Systems, Inc. West Lafayette, IN, USA), respectively. Electrochemical measurements were
131 carried out using a microfabricated electrochemical cell with three electrodes (gold working
132 and counter electrodes, and silver reference electrode). All the potentials were referred to
133 Ag. EIS measurements were performed using a PGSTAT128N potentiostat from Metrohm
134 Autolab, with a NOVA 1.11 electrochemical analysis software.

135 Scanning electron microscope images were taken on a LEO 1450VP instrument
136 (UK), equipped with an Energy Dispersive Spectrometer analyzer, Genesis 2000 (England).
137 Sputtering deposition was made with a SPI-Module Sputter Coater (Structure Probe Inc,
138 West Chester, PA). The electrode thickness was controlled using a Quartz Crystal
139 Thickness Monitor model 12161 (SPI-Module, Structure Probe Inc, West Chester, PA).

140 A syringe pumps system (Baby Bee Syringe Pump, Bioanalytical Systems, Inc.
141 West Lafayette, IN, USA) was used for introducing the solutions in the device. All
142 solutions employed were injected using syringe pumps at flow rate of 2 $\mu\text{L min}^{-1}$. All
143 solutions and reagent temperatures were conditioned before the experiment using a Vicking
144 Masson II laboratory water bath (Vicking SRL, Buenos Aires, Argentina). Absorbance was

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

145 detected by Bio-Rad Benchmark microplate reader (Japan) and Beckman DU 520 general
146 UV/VIS spectrophotometer. All pH measurements were made with an Orion Expandable
147 Ion Analyzer (Orion Research Inc., Cambridge, MA, USA) Model EA 940 equipped with a
148 glass combination electrode (Orion Research Inc).

150 **2.3. Fabrication of the microfluidic device**

151 The microfluidic device manufacture involved four steps: i) Deposition of Ag/Au
152 electrodes by sputtering on a glass plate, ii) Fabrication of the PMDS molds by
153 photolithography, iii) CMK-8-CH deposition on the Au working electrode (GE), and iv)
154 Sealing of the glass/PDMS. The fabrication of the microfluidic electrochemical
155 immunosensor was carried out according to the procedure previously reported with the
156 following modifications [18] (Scheme 1): For the construction of the electrode, a self-
157 adhesive vinyl sheet patterned mask was employed. The mask was positioned at the end of
158 the central channel (CC), followed by sputtering deposition of 100 nm silver and 100 nm
159 gold over a glass plate. The vinyl mask was removed after sputtering, leaving the gold and
160 silver tracks on the glass. The geometric area was 1.0 mm² for the working electrode, and
161 2.0 mm² for the counter and reference electrodes.

162 PDMS microchannels were cast by photolithography. The channels design in the
163 negative mask was generated by a computer program. The replication master was patterned
164 with a SU-8 photoresist layer over a silicon wafer using a spin coater at 2200 rpm for 30 s,
165 and baked at 60 °C for 2 min and 90 °C for 5 min. Then, the coated sheet was exposed to a
166 UV lamp through a negative mask with the T-configuration design (two inlets for reagents
167 and buffer, respectively and one outlet) with 200-µm-width and 100-µm-high, with a
168 central channel (CC) (40 mm length, 200-µm-width, and 100-µm-high). After that, the

1
2
3
4 169 unexposed photoresist was removed. Then, the Sylgard curing agent was mixed with
5
6 170 PDMS prepolymer (1:10), and placed on the replication master (degassed for 30 min to
7
8
9 171 eliminate air bubbles). The polymer curing process was carried out in a hot plate at 70 °C
10
11 172 for 45 h. The PDMS was then peeling off, and the external access to the microfluidic device
12
13
14 173 was obtained by drilling holes. After that, the glass plate and PDMS were placed in oxygen
15
16 174 plasma for 1 min and were contacted immediately for a strong seal.
17
18
19 175

20 21 176 **2.4. Synthesis of CMK-8**

22
23 177 As mentioned before, CMK-8 was prepared using KIT-6 as a hard template. KIT-6
24
25
26 178 was synthesized according to a procedure previously reported with slight modifications
27
28 179 [37]. Firstly, 9.6g:346.6g:18.8g of P123, double distilled water and HCl, respectively, were
29
30
31 180 mixed. After P123 dissolution, 9.6 g of butanol were added, and the solution was stirred for
32
33 181 1 h at 35 °C, followed by addition of 24.8 g TEOS with continuous stirring at 35 °C for 12
34
35
36 182 h. Then, the temperature was raised at 120 °C for 24 h. The white precipitate was washed
37
38 183 by double distilled water several times, and dried at 120 °C. KIT-6 was obtained after
39
40
41 184 calcination at 550 °C for 3 h.

42
43 185 CMK-8 was synthesized following the procedure with some modifications [36].
44
45 186 Sucrose was used as a carbon source. Firstly, 0.5g:0.6g:0.1g:5mL KIT-6, sucrose, H₂SO₄
46
47
48 187 and H₂O were mixed and stirred for 15 min. Then, the suspension was dried at 100 °C for 6
49
50
51 188 h, followed by increasing the temperature at 160 °C for another 6 h. After that, a second
52
53 189 impregnation step was carried out to ensure the KIT-6 pores filling by adding
54
55 190 2mL:0.4g:0.05g H₂O, sucrose and H₂SO₄, followed by the temperature treatment. The dark
56
57
58 191 brown mixture was carbonized at 900 °C in N₂ for 6 h to achieve complete carbonization.
59
60 192 Lastly, the powder was washed several times with 2 mol L⁻¹ NaOH in order to remove the
61
62
63
64
65

1
2
3
4 193 inorganic silica template. The black solid was filtered and washed with ethanol:NaOH
5
6 194 (50:50 % v/v), and finally dried at 120 °C for 12 h.

7
8
9 195 In order to improve the hydrophilicity of mesoporous carbon for the electrochemical
10
11 196 use in sensors, CMK-8 was treated with 70 % HNO₃ at 60 °C for 1 h and subsequently
12
13
14 197 washed with double distilled water until neutral pH [34]. CMK-8 was characterized by
15
16 198 transmission electron microscopy (TEM), and N₂ adsorption-desorption isotherms.

17
18
19 199

20 200 **2.5. CMK-8-CH/GE preparation**

21
22
23 201 A chitosan solution was prepared by adding 1 g of CH in 100 mL of an ethanol:H₂O
24
25 202 (1:4) mixture at pH 3.00 with HCl addition under stirring conditions. The undissolved
26
27 203 material was filtered. Then, the pH value was gradually increased to 8.00 with NaOH. 1 %
28
29 204 CH solution was stored at 4 °C until use [38].

30
31
32
33 205 After that, 0.9 mg of CMK-8 was dispersed in 1 mL of 1 % CH with the ultrasonic
34
35 206 stirring aid for 1 h. The CMK-8-CH suspension was stable for at least 2 months at 4 °C.
36
37 207 Finally, 10 µL of the obtained CMK-8-CH were dropped on the GE, and the solvent was
38
39 208 evaporated under an infrared heat lamp. CMK-8-CH/GE was characterized by scanning
40
41 209 electron microscopy (SEM), energy dispersive spectrometry (EDS), cyclic voltammetry
42
43 210 (CV), and electrochemical impedance spectroscopy (EIS).

44
45
46
47 211

48 212 **2.6. Synthesis of core-shell AuNPs@Fe₃O₄**

49
50
51 213 Firstly, Fe₃O₄ nanoparticles were prepared by co-precipitation method following the
52
53 214 procedure previously published by Salihov et al. with some modifications [29]. Briefly, a
54
55 215 100 mL 0.1 mol L⁻¹ FeCl₂ and 0.2 mol L⁻¹ FeCl₃ solution was prepared with 0.1 mol L⁻¹
56
57
58 216 HCl. Then, 1 mol L⁻¹ NaOH was added dropwise under stirring condition at 75 °C for 50

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

217 min under N₂ atmosphere. The black suspension obtained was separated using a
218 neodymium magnet, and washed several times using N₂ purged double distilled water. The
219 Fe₃O₄ nanoparticles suspension was dried in vacuum oven and kept at 4 °C for further use.

220 After that, Fe₃O₄ nanoparticles were resuspended in double distilled water, and the
221 suspension was ultrasonicated for 15 min. Then, 1 mL of 0.1 mol L⁻¹ HAuCl₄ solution was
222 added to the suspension in stirring condition at 75 °C. Finally, 5 mL of 0.1 mol L⁻¹
223 trisodium citrate dehydrate solution were added to the mixture [39]. The solution was
224 stirred at 75 °C for 45 min until a reddish color suspension. AuNPs@Fe₃O₄ nanoparticles
225 were washed several times using N₂ purged double distilled water using a neodymium
226 magnet. The suspension was dried in vacuum oven and kept at 4 °C for further use.
227 AuNPs@Fe₃O₄ was characterized by SEM and EDS.

228

229 **2.7. *T. canis* second-stage larvae (TES) antigen preparation**

230 TES antigens were obtained according to the technique described by Gillespie [13].
231 TES were maintained at 35 °C with 5 % CO₂ atmosphere and adjusted to pH 6.5 in Iscove's
232 modified Dulbecco's culture medium supplemented with HEPES buffer and a Penicillin-
233 Streptomycin solution. The culture supernatant was removed weekly, and the supernatant
234 pool was kept at -70 °C. The supernatant pool was concentrated by filtration through
235 polyethersulphone membranes and dialysed. The protein content was then estimated by the
236 Bradford method with bovine albumin as the standard protein.

237

238 **2.8. TES immobilization on AuNPs@Fe₃O₄**

239 10 mg of AuNPs@Fe₃O₄ were resuspended with MPA 50 mmol L⁻¹ in an
240 EtOH:H₂O (75:25, v/v) mixture for 12 h at 25 °C. The thiol group of MPA reacts with the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

241 Au surface, giving, as a result, free carboxylic groups, which are activated by rinsing with
242 an EDC:NHS solution in 10 mmol L⁻¹ phosphate buffer saline (PBS) for 2 h at pH 7.00.
243 Then, the AuNPs@Fe₃O₄ nanoparticles were washed several times using a neodymium
244 magnet and dried with N₂.

245 After that, the AuNPs@Fe₃O₄ were put in contact with 1 mL of 100 µg mL⁻¹ TES
246 solution in 10 mmol L⁻¹ PBS pH 7.00 for 10 h at 4 °C. Finally, the nanoparticles were
247 rinsed with 10 mmol L⁻¹ PBS pH 7.00 and stored in the same buffer at 4 °C when not in
248 use. The immobilized antigen preparation was perfectly stable for at least 1 month. Scheme
249 2 shows the procedure for TES-AuNPs@Fe₃O₄ preparation.

250

251 **2.9. Analytical procedure for anti-*T. canis* IgG antibodies determination**

252 In this work, six serum samples obtained from patients with toxocariasis were
253 analyzed. These samples showed a marked reactivity against *T. canis*. The procedure for
254 anti-*T. canis* IgG antibodies determination involves the following steps. Firstly, TES-
255 AuNPs@Fe₃O₄ was introduced into the microfluidic channel and kept in the central
256 channel using an external neodymium magnet. To avoid the unspecific bindings, a blocking
257 treatment was carried out through with 1 % of bovine serum albumin (BSA) in 10 mmol L⁻¹
258 PBS pH 7.00 for 5 min, followed by a washing step with 10 mmol L⁻¹ PBS pH 7.00 for 2
259 min.

260 Then, the serum samples (previously diluted 50-fold with 10 mmol L⁻¹ PBS pH
261 7.00), were injected for 5 min, followed by the washing step to remove the excess of the
262 sample. In this step, the IgG specific antibodies to *T. canis* present in the samples react with
263 TES immobilized on AuNPs@Fe₃O₄ surface. Later, IgG anti-*T. canis* were quantified by
264 using a second antibody labeled with horseradish peroxidase (HRP-anti-IgG). HRP

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

265 catalyzes the reduction of H_2O_2 to H_2O , with the subsequent oxidation of catechol (H2Q) to
266 p-benzoquinone (Q). Finally, the substrate solution ($1 \text{ mmol L}^{-1} \text{ H}_2\text{O}_2 + 1 \text{ mmol L}^{-1} \text{ 4-TBC}$
267 in 10 mmol L^{-1} phosphate-citrate buffer pH 5.00) was pumped, and the enzymatic product
268 was detected by amperometry at -100 mV in the CMK-8-CH/GE (Scheme 2).

269 Before each sample analysis, the immunosensor was exposed to a desorption buffer
270 (0.1 mol L^{-1} citrate-HCl pH 2.00) for 5 min and then washed with 10 mmol L^{-1} PBS pH
271 7.00. This procedure desorbed the anti-*T. canis* antibodies bound to immobilized TES,
272 allowing to performed a new determination. The device can be used without significant loss
273 of sensitivity for 1 month (decrease of 10 %). The microfluidic immunosensor was stored
274 in 10 mmol L^{-1} PBS pH 7.00 at $4 \text{ }^\circ\text{C}$.

275

276 **3. Results and discussion**

277 **3.1. CMK-8-CH/Au and AuNPs@Fe₃O₄ characterization**

278 CMK-8 specific surface area (SBET) was calculated according to the Brunauer-
279 Emmet-Teller method, using the adsorption data at relative pressures. Total pore volume
280 (VTP) was found by the Gurvich's rule. CMK-8 pore size distribution (PSD) was
281 determined by VBS macroscopic method using the adsorption branch data [38]. Figure 1 a)
282 shows a TEM image of CMK-8. The micrograph reveals a uniform long-range ordered
283 mesoporous cubic pore structure with a 10 nm pore size approximately. Also, a study on
284 the N_2 adsorption-desorption isotherm at 77 K was carried out, and a type IV isotherm with
285 an H2 hysteresis loop characteristic of mesoporous materials can be clearly seen (Figure 1
286 b). CMK-8 textural properties, obtained from adsorption data, were SBET: $817 \text{ m}^2 \text{ g}^{-1}$, and
287 VTP: $0.7 \text{ cm}^3 \text{ g}^{-1}$. Figure 1 b) (inset), confirming that CMK-8 has a narrow pore size
288 distribution around 9 nm.

1
2
3
4 289 Morphology of the CMK-8-CH/GE nanocomposite film was analyzed by SEM.
5
6 290 Figure 1 c) reveals a uniform CMK-8-CH film over the gold electrode surface. The
7
8
9 291 nanocomposite three-dimensional structure film provides a suitable surface for a conductive
10
11 292 pathway for electron-transfer. The nanocomposite elemental composition was determined
12
13
14 293 by EDS. Figure 1 d) shows five peaks, corresponding to C, O, Si, Au, and Ag elements,
15
16 294 respectively.

17
18 295 CV of $[\text{Fe}(\text{CN})_6]^{3-/4-}$ couple is an appropriate tool to study the electrode surface
19
20
21 296 properties during several modification steps. Accordingly, Figure 2 a) shows CVs recorded
22
23
24 297 with a bare GE and the CMK-8-CH/GE. Well-defined CVs characteristics of a diffusion-
25
26 298 controlled redox process were perceived at the bare GE, whereas enlarged peaks were
27
28
29 299 noticed with the electrode modified with CMK-8-CH. The higher faradaic response
30
31 300 observed with the CMK-8-CH/GE can be attributed to the increased electroactive surface
32
33 301 area, and the excellent electrical conductivity of CMK-8. Another factor to take account is
34
35
36 302 the hydrophilic surface obtained due to the synergic effect between CMK-8 and chitosan,
37
38 303 which allow to improve the solution/electrode contact.

39
40 304 Electrochemical impedance spectroscopy was recorded in $5 \text{ mmol L}^{-1} [\text{Fe}(\text{CN})_6]^{4-/3-}$
41
42
43 305 in $0.1 \text{ mol L}^{-1} \text{ KCl}$, applying a $+150 \text{ mV}$ potential and varying the frequency with
44
45
46 306 logarithmic spacing frequency in the range from 0.1 Hz to 100 kHz . EIS data were
47
48 307 represented in Nyquist plots (Fig. 2 b)), where the impedance spectrums includes a
49
50
51 308 semicircle at higher frequencies that represents the electron transfer resistance (evidencing
52
53 309 the blocking behavior of the bare/modified electrode surface towards the redox couple), and
54
55 310 a linear part at lower frequencies that represents the diffusion process. The analytical signal
56
57
58 311 considered is the R_{ct} , evaluated by the iterative fitting of the experimental data to the
59
60 312 modified Randles equivalent circuit (Fig. 2 b), inset), where R_s is the solution resistance, Z_w

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

313 is the Warburg impedance, and CPE is the constant phase element. As can be observed, the
314 bare GE displays a lower electron transfer resistance (69 Ω), and the semicircle increased
315 (R_{ct} = 143 Ω) for the CH/GE due to the presence of an insulating layer formed as a
316 consequence of the CH polymer deposition process. Such partial blockage of the electron
317 transfer is then alleviated for the CMK-8-CH/GE, because of the excellent electrical
318 conductivity of CMK-8, hence a decrease in the semicircle curve (R_{ct} = 19 Ω) was noticed.

319 As shown in Figure 2 c), a linear relationship between redox peak current and the
320 square root of the scan rate is established in the 25 to 200 mV s^{-1} range, indicating the
321 electron-transfer process is diffusion controlled for the CMK-8-CH/GE. The apparent
322 electroactive surface area of this modified electrode can be calculated by the Randles-
323 Sevcik equation and the value was found to be 0.195 cm^2 .

324 Regarding the AuNPs@Fe₃O₄ nanoparticles characterization, Figure 3 a) shows the
325 SEM images, and the nanoparticles diameters ranged from 10 to 50 nm. The nanoparticles
326 elemental composition was determined by EDS and the O, Fe, and Au typical peaks can be
327 clearly seen (Figure 3 b)).

328

329 **3.2. Optimization of experimental parameters**

330 Experimental parameters that affect the IgG anti-*T. canis* quantitation in biological
331 samples were studied. For this purpose, an anti-*T. canis* IgG standard solution of 40 ng mL^{-1}
332 was employed.

333 Firstly, the optimal flow rate for samples and reagents was analyzed employing
334 several flow rates and evaluating the generated current during the immune reaction. As
335 shown in Figure 4 a), flow rates varied from 1 to 2.5 $\mu\text{L min}^{-1}$, showing an increase in the
336 current response with the flow rate until 2.5 $\mu\text{L min}^{-1}$. Then, the signal decreased slightly

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

337 due to the high flow reduced the interaction time between the immune reagents. Therefore,
338 a flow rate of $2 \mu\text{L min}^{-1}$ was used for reagents, samples, and washing solutions.

339 The influence of pH on the enzymatic response under flow conditions was also
340 examined in the range from 4.00 to 6.50 (Figure 4 b). A current increase until pH 5.00 can
341 be observed followed by a decrease at higher pH values up to pH 6.50. So, the pH 5.00 was
342 selected as optimum in 10 mmol L^{-1} phosphate-citrate buffer.

343 CMK-8 concentration employed for the gold electrode surface modification was
344 also optimized. This study was carried out in the 0.5 to 1.2 mg mL^{-1} range. A significant
345 signal increase was observed from 0.5 to 0.9 mg mL^{-1} . However, at higher concentrations,
346 insignificant differences were obtained. Then, 0.9 mg mL^{-1} CMK-8 was employed for the
347 modification step (Figure 4 c)).

348 An important parameter to be optimized was the concentration of the *T. canis*
349 second-stage larvae (TES) to be immobilized in the AuNPs@Fe₃O₄. Such study was
350 performed from 10 to $125 \mu\text{g mL}^{-1}$ TES, and the current response increased until $100 \mu\text{g}$
351 mL^{-1} TES. No significant changes were observed for higher TES concentrations, hence 100
352 $\mu\text{g mL}^{-1}$ TES was employed as an optimum concentration for AuNPs@Fe₃O₄
353 immobilization (Figure 4 d)).

354 Other important parameters such as CH concentration, amount of AuNPs@Fe₃O₄
355 nanoparticles, among others, were also optimized (Data not shown).

356

357 **3.4. Analytical performance of the microfluidic immunosensor**

358 The analytical performance of our immunosensor was studied by measuring the
359 response towards varying concentrations of anti-*T. canis* IgG in the 0.1 - 100 ng mL^{-1}
360 concentration range. A linear relationship was observed between 0.33 - 75 ng mL^{-1} . The

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

361 calibration curve was obtained by plotting current (nA) versus anti-*T. canis* IgG
362 concentration (ng mL⁻¹). The calibration curve was defined by ΔI (nA) = 15.86 – 2.21 C_T,
363 *canis* with a correlation coefficient of 0.992, where ΔI is the difference between blank and
364 sample current. The standard deviation (SD) for the calibration curve was 4.45. The
365 coefficient of variation (CV) for the determination of 40 ng mL⁻¹ anti-*T. canis* IgG was
366 below 4.92% (n=5). These values demonstrate that our microfluidic electrochemical
367 immunosensor can be used to anti-*T. canis* IgG quantification in unknown samples. The
368 limit of detection (LD) and the limit of quantification (LQ) were calculated according the
369 IUPAC recommendations. For the electrochemical detection procedure, the LD and LQ
370 were 0.10 and 0.5 ng mL⁻¹, respectively.

371 The precision of the electrochemical assay was checked with six anti-*T. canis* IgG
372 standard solutions. The within-assay precision was tested with five measurements on the
373 same day. These analyses were repeated for three consecutive days in order to estimate
374 between-assay precision. The assay showed excellent precision; the CV % within-assay
375 values were below 5 %, and the between-assay values were below 6 % (Table 1). The total
376 assay time for anti-*T. canis* IgG determination was 20 min, much less than the time
377 generally used for the conventional ELISA.

378 The electrochemical method was compared with the fluorescent immunosensor
379 previously reported, where IgG anti-*T. canis* was quantified using 3-aminopropyl-
380 functionalized silica-nanoparticles (AP-SNs) and cadmium selenide zinc sulfide quantum
381 dots (CdSe-ZnS QDs) [13]. The slope obtained was practically close to the unit, indicating
382 a good correspondence between both methods. Compared with the fluorescent
383 immunosensor, the electrochemical immunosensor showed an improved LD. The F-test
384 value for the immunosensor was 0.43 (the F-test value is 2.26 at a 95 % confidence level).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

385 In order to evaluate the analytical applicability of the electrochemical immunosensor, IgG
386 anti-*Toxocara canis* quantification was carried out in six human serum samples with
387 toxocariasis, under the conditions previously described. These samples were confirmed by
388 fluorescent immunosensor and commercial ELISA. The samples analyzed revealed similar
389 IgG anti-*T. canis* concentrations, as can be observed in Table 2.

390

391 **4. Conclusions**

392 The designed microfluidic electrochemical immunosensor for IgG anti-*T. canis*
393 detection in human serum samples shows outstanding analytical parameters. Our analytical
394 method is based on the covalently immobilization of *T. canis* second-stage larvae antigens
395 on core-shell gold nanoparticles-ferric oxide (AuNPs@Fe₃O₄) retained by an external
396 magnet in the microfluidic channel. IgG anti-*T. canis* antibodies detection was carried out
397 using a non-competitive immunoassay. The enzyme electrochemical mediator was
398 measured over the order mesoporous carbon-chitosan (CMK-8-CH) modified gold
399 electrode. The synthesized CMK-8 showed high specific surface area, large pore volume,
400 uniform mesostructure, good conductivity, and excellent electrochemical activity, that
401 allowed us to greatly improve the surface area of the sensor and its analytical performance.

402 The total assay time employed was shorter than the time reported for commercial
403 ELISA frequently used. The microfluidic electrochemical immunosensor offered several
404 attractive advantages like high stability, high selectivity, and sensitivity. In conclusion, the
405 device could be well suitable for biomedical sensing and clinical applications for diagnosis
406 and prognosis of toxocariosis in serum human samples.

407

408 **Acknowledgements**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

409 The authors wish to thank the financial support from the Universidad Nacional de
410 San Luis (PROICO-1512-22/Q232), the Agencia Nacional de Promoción Científica y
411 Tecnológica, the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
412 (PICT-2015-2246, PICT 2015-3526, PICT-2015-1575, PICT-2014-1184, PICT-2013-3092,
413 PICT-2013-2407), and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
414 (2019/06293-6).
415

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

416 **References**

417 [1] P. Nejsum, M. Betson, R.P. Bendall, S.M. Thamsborg, J.R. Stothard, Assessing the
418 zoonotic potential of *Ascaris suum* and *Trichuris suis*: looking to the future from an
419 analysis of the past, *J. Helminthol.* 86 (2012) 148-155.

420 [2] D. Choi, J. Lim, D. Choi, S. Paik, S. Kim, S. Choi, Toxocariasis and ingestion of raw
421 cow liver in patients with eosinophilia, *Korean J. Parasitol.* 46 (2008) 139-143.

422 [3] S. Archelli, G. Santillan, R. Fonrouge, G. Céspedes, L. Burgos, N. Radman,
423 Toxocariasis: seroprevalence in abandoned institutionalized children and infants, *Rev.*
424 *Argent. Microbiol.* 46 (2014) 3-6.

425 [4] A.J. Cassenote, A.R. de Abreu Lima, J.M. Pinto Neto, G. Rubinsky-Elefant,
426 Seroprevalence and modifiable risk factors for *Toxocara* spp. in Brazilian
427 schoolchildren, *PLoS. Neglect. Trop. D.* 8 (2014) 2830.

428 [5] L.R. Mendonca, R.V Veiga, V.C.C Dattoli, C.A. Figueiredo, R. Fiaccone, J. Santos,
429 A.A. Cruz, L.C. Rodrigues, P.J. Cooper, L.C. Pontes-de-Carvalho, M.L. Barreto, N.M.
430 Alcantara-Neves, *Toxocara* seropositivity, atopy and wheezing in children living in
431 poor neighbourhoods in urban Latin American, *PLoS. Neglect. Trop. D.* 6 (2012) 1886.

432 [6] E.V. Guilherme, A.A. Marchioro, S.M. Araujo, D.L. Falavigna, C. Adami, G.
433 Falavigna-Guilherme, G. Rubinsky-Elefant, A.L. Falavigna-Guilherme, Toxocariasis
434 in children attending a public health service pneumology unit in Parana State, Brazil,
435 *Rev. Inst. Med. Trop.* 55 (2013) 189-192.

436 [7] J.K. Magnaval, L. Glickman, P. Dorchies, B. Morassin, Highlights of human
437 Toxocariasis, *Korean J. Parasitol.* 39 (2001) 1-11.

438 [8] J. Fillaux, J.F. Magnaval, Laboratory diagnosis of human toxocariasis, *Vet. Parasitol.*
439 193 (2013) 327-336.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

440 [9] H. Smith, C. Holland, M. Taylor, J.F. Magnaval, P. Schantz, Maizels R. How common
441 is human toxocariasis? Towards standardizing our knowledge. Trends. Parasitol. 25
442 (2009) 182-188.

443 [10] I.C. Prado, V.G. Mendes, A.L.A. Souza, R.F. Dutra, S.G. De-Simone, Electrochemical
444 immunosensor for differential diagnostic of *Wuchereria bancrofti* using a synthetic
445 peptide, Biosens. Bioelectron. 113 (2018) 9-15.

446 [11] J. Ramos-Jesus, L.C. Pontes-de-Carvalho, S.M. Barrouin Melo, N.M. Alcântara-
447 Neves, R.F. Dutra, A gold nanoparticle piezoelectric immunosensor using a
448 recombinant antigen for detecting *Leishmania infantum* antibodies in canine serum,
449 Biochem. Eng. J. 110 (2016) 43-50.

450 [12] S.V. Pereira, F.A. Bertolino, M.A. Fernández-Baldo, G.A. Messina, E. Salinas, M.I.
451 Sanz, J. Raba, Microfluidic device based on a screen-printed carbon electrode with
452 electrodeposited gold nanoparticles for the detection of IgG anti-*Trypanosoma cruzi*
453 antibodies, Analyst. 136 (2011) 4745-4751.

454 [13] V. Medawar, G.A. Messina, M.A. Fernández Baldo, J. Raba, S.V. Pereira, Fluorescent
455 immunosensor using AP-SNs and QDs for quantitation of IgG anti-*Toxocara canis*,
456 Microchem. J. 130 (2017) 436-441.

457 [14] Serological diagnosis of Toxoplasmosis disease using a fluorescent immunosensor
458 with chitosan-ZnO-nanoparticles, V. Medawar-Aguilar, C.F. Jofre, M.A. Fernández-
459 Baldo, A. Alonso, S. Angel, J. Raba, S.V. Pereira, G.A. Messina, Anal. Biochem. 564-
460 565 (2019) 116-122.

461 [15] E.A. Takara, S.V. Pereira, M.L. Scala-Benuzzi, M.A. Fernández-Baldo, J. Raba, G.A.
462 Messina, Novel electrochemical sensing platform based on a nanocomposite of PVA /

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

463 PVP / RGO for IgG anti- *Toxoplasma gondii* antibodies quantification, *Talanta*. 195
464 (2019) 699-705.

[16] M. Regiart, M. Rinaldi-Tosi, P.R. Aranda, F.A. Bertolino, J. Villarroel-Rocha, K.
465 Sapag, G.A. Messina, J. Raba, M.A. Fernández-Baldo, Development of a
466 nanostructured immunosensor for early and in situ detection of *Xanthomonas*
467 *arboricola* in agricultural food production, *Talanta*. 175 (2017) 535-541.

[17] F.G. Ortega, M.A. Fernández-Baldo, M.J. Serrano, G.A. Messina, J.A. Lorente, J.
470 Raba, Epithelial cancer biomarker EpCAM determination in peripheral blood samples
471 using a microfluidic immunosensor based in silver nanoparticles as platform, *Sens.*
472 *Actuators. B. Chem.* 221 (2015) 248-256.

[18] M. Regiart, M.A. Fernández-Baldo, J. Villarroel-Rocha, G.A. Messina, F.A. Bertolino,
473 K. Sapag, A.T. Timperman, J. Raba, Microfluidic immunosensor based on mesoporous
474 silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid
475 modified gold electrode for cancer biomarker detection, *Anal. Chim. Acta.* 963 (2017)
476 83-92.

[19] F. Tan, P.H.M. Leung, Z.B. Liu, Y. Zhang, L. Xiao, W. Ye, X. Zhang, L. Yi, M. Yang,
478 A PDMS microfluidic impedance immunosensor for *E. coli* O157:H7 and
479 *Staphylococcus aureus* detection via antibody-immobilized nanoporous membrane,
480 *Sens. Actuators. B. Chem.* 159 (2011) 328-335.

[20] J. Casanova-Moreno, J. To, C.W.T. Yang, R.F.B. Turner, D. Bizzotto, K.C. Cheung,
481 Fabricating devices with improved adhesion between PDMS and gold-patterned glass,
482 *Sens. Actuators. B. Chem.* 246 (2017) 904-909.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

[21] A. Waheed, M. Mansha, N. Ullah, Nanomaterials-based electrochemical detection of heavy metals in water: Current status, challenges and future direction, TrAC-Trend. Anal. Chem. 105 (2018) 37-51.

[22] L. Reverté, B. Prieto-Simón, M. Campàs, New advances in electrochemical biosensors for the detection of toxins: Nanomaterials, magnetic beads and microfluidics systems. A review, Anal. Chim. Acta. 908 (2016) 8-21.

[23] T. Hong, W. Liu, M. Li, C. Chen, Recent advances in the fabrication and application of nanomaterial-based enzymatic microsystems in chemical and biological sciences. Anal. Chim. Acta. 1067 (2019) 31-47.

[24] X. Wang, R. Niessner, D. Tang, D. Knopp, Nanoparticle-based immunosensors and immunoassays for aflatoxins. Anal. Chim. Acta. 912 (2016) 10-23.

[25] Z. Abed, J. Beik, S. Laurent, N. Eslahi, T. Khani, E.S. Davani, H. Ghaznavi, A. Shakeri- Zadeh, Iron oxide–gold core–shell nano-theranostic for magnetically targeted photothermal therapy under magnetic resonance imaging guidance, J. Cancer. Res. Clin. 145 (2019) 1213-1219.

[26] C. Karami, M.A. Taher, A catechol biosensor based on immobilizing laccase to Fe₃O₄@Au core-shell nanoparticles, Int. J. Biol. Macromol. 129 (2019) 84-90.

[27] E. Rasouli, W.J. Basirun, M.R. Johan, M. Rezayi, M. Darroudi, K. Shameli, Z. Shanavaz, O. Akbarzadeh, Z. Izadiyan, Facile and greener hydrothermal honey- based synthesis of Fe₃O₄/Au core/shell nanoparticles for drug delivery applications, J. Cell. Biochem. (2018) 1-8.

[28] S. Sabale, P. Kandesar, V. Jadhav, R. Komorek, R.K. Motkuri, X.Y. Yu, Recent development in synthesis, properties, and biomedical applications of core/shell

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

508 superparamagnetic iron oxide nanoparticles with gold, *Biomater. Sci.* 5 (2017) 2212-
509 2225.

[29] S.V. Salihov, Y.A. Ivanenkov, S.P. Krechetov, M.S. Veselov, N.V. Sviridenkova,
510 A.G. Savchenko, N.L. Klyachko, Y.I. Golovin, N.V. Chufarova, E.K. Beloglazkina,
511 A.G. Majouga, Recent advances in the synthesis of Fe₃O₄@Au core/shell
512 nanoparticles, *J. Magn. Magn. Mater.* 394 (2015) 173-178.

[30] A. Sood, V. Arora, J. Shah, R.K. Kotnala, T.K. Jain, Multifunctional gold coated iron
513 oxide core-shell nanoparticles stabilized using thiolated sodium alginate for biomedical
514 applications. *Materials Science and Engineering C* 80 (2017) 274-281.

[31] Y. Yuan, S. Li, Y. Xue, J. Liang, L. Cui, Q. Li, S. Zhou, Y. Huang, G. Li, Y. Zhao, A
515 Fe₃O₄@Au-based pseudo-homogeneous electrochemical immunosensor for AFP
516 measurement using AFP antibody-GNPs-HRP as detection probe, *Anal. Biochem.* 534
517 (2017) 56-63.

[32] J. Gao, X. Wang, Y. Zhang, J. Liu, Q. Lu, M. Chen, Y. Bai, Preparation and
518 supercapacitive performance of nanosized manganese dioxide/ordered mesoporous
519 carbon composites, *Electrochim. Acta.* 192 (2016) 234-242.

[33] R. Guo, L. Zhao, W. Yue, Assembly of core-shell structured porous carbon-graphene
520 composites as anode materials for lithium-ion batteries, *Electrochim. Acta.* 152 (2015)
521 338-344.

[34] J. Hu, M. Noked, E. Gillette, Z. Gui, S. B. Lee, Capacitance behavior of ordered
522 mesoporous carbon/Fe₂O₃ composites: Comparison between 1D cylindrical, 2D
523 hexagonal, and 3D bicontinuous mesostructures, *Carbon.* 93 (2015) 903-914.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

530 [35] R.J. Kalbasi, S.F. Rezayi, A novel bi-functional metal/solid acid catalyst for the direct
531 reductive amination of nitroarenes synthesized on a resistant mesoporous carbon
532 (CMK-8) support, *J. Porous. Mat.* 26 (2019) 641-654.

533 [36] T.N. Phan, M.K. Gong, R. Thangavel, Y.S. Lee, C.H. Ko, Enhanced electrochemical
534 performance for EDLC using ordered mesoporous carbons (CMK-3 and CMK-8): Role
535 of mesopores and mesopore structures, *J. Alloy. Compd.* 780 (2019) 90-97.

536 [37] T.N. Phan, M.K. Gong, R. Thangavel, Y.S. Lee, C.H. Ko, Ordered mesoporous carbon
537 CMK-8 cathodes for high-power and long-cycle life sodium hybrid capacitors, *J.*
538 *Alloy. Compd.* 743 (2018) 639-645.

539 [38] M. Regiart, J.L. Magallanes, D. Barrera, J. Villarroel-Rocha, K. Sapag, J. Raba, F.A.
540 Bertolino, An ordered mesoporous carbon modified electrochemical sensor for solid-
541 phase microextraction and determination of triclosan in environmental samples, *J.*
542 *Sensor. Actuat. B-Chem.* 232 (2016) 765-772.

543 [39] Y.-R. Cui, C. Hong, Y.-L. Zhou, Y. Li, X.-M. Gao, X.-X. Zhang, Synthesis of
544 orientedly bioconjugated core/shell Fe₃O₄@Au magnetic nanoparticles for cell
545 separation, *Talanta.* 85 (2011) 1246-1252.

546
547

1
2
3
4 548 **Figure captions**

5
6 549 **Scheme 1.** Microfluidic device fabrication by photolithography.

7
8
9 550 **Scheme 2.** Analytical procedure for IgG anti-*T. canis* determination in human serum
10
11 551 samples.

12
13
14 552 **Figure 1.** a) TEM image of CMK-8, b) N₂ adsorption-desorption isotherm at 77 K, and
15
16 553 PSD (inset) of CMK-8, c) SEM micrograph of CMK-8-CH/GE, and d) EDS of CMK-8-
17
18 554 CH/GE.

19
20
21 555 **Figure 2.** a) Cyclic voltammograms recorded in a 1 mmol L⁻¹ [Fe(CN)₆]^{3-/4-} in 0.1 mol L⁻¹
22
23 556 KCl solution with a bare GE (b), and a CMK-8-CH/GE (c). Curve (a) corresponds to the
24
25 557 CV recorded in the 0.1 mol L⁻¹ KCl supporting electrolyte solution with the bare GE (Scan
26
27 558 rate = 75 mV s⁻¹), b) EIS recorded in 5 mmol L⁻¹ [Fe(CN)₆]^{3-/4-} in 0.1 mol L⁻¹ KCl, at 150
28
29 559 mV, varying the frequency with logarithmic spacing frequency in the range from 0.1 Hz to
30
31 560 100 kHz with bare GE, CH/GE, and CMK-8-CH/GE, and c) Cyclic voltammograms
32
33 561 recorded in a 1 mmol L⁻¹ [Fe(CN)₆]^{3-/4-} in 0.1 mol L⁻¹ KCl solution with the CMK-8-
34
35 562 CH/GE at different scan rates (from a-h): 25, 50, 75 100, 125, 150, 175, 200 mV s⁻¹. The
36
37 563 inset shows a plot of peak current values (I_p) as a function of the square root of the scan
38
39 564 rate (v^{1/2}).


40
41
42 565 **Figure 3.** a) SEM micrograph of AuNPs@Fe₃O₄, and b) EDS of AuNPs@Fe₃O₄.

43
44
45 566 **Figure 4.** (a) Optimization of microfluidic device flow rate, (b) Optimization of pH
46
47 567 enzymatic response, (c) Optimization of CMK-8 concentration employed for the electrode
48
49 568 surface modification, and (d) Optimization of *T. canis* second-stage larvae (TES) antigens
50
51 569 immobilization.

52
53
54
55
56
57
58 570

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

571



572





573

574

575

Scheme 1

1
2
3
4 581



40 582
41
42 583
43
44
45 584
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1

585




Figure 2

586


587

588

589

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

590



591

Figure 3

592

593

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

594




Figure 4

595

596

597

598

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

599

600 **Table 1.** Within-assay precision and between-assay precision for the microfluidic
601 electrochemical immunosensor.

Samples ^a	Within-assay		Between-assay	
	Mean ^b	CV %	Mean	CV %
1	1.05	3.9	1.06	4.1
5	5.09	4.3	5.10	4.7
10	9.89	3.8	10.28	5.1
25	25.41	4.9	25.71	5.8
50	49.91	3.1	50.91	5.5
70	70.61	4.5	70.82	4.9

602 ^a Human serum samples ng mL⁻¹ IgG anti-*T. canis* antibody.
603 ^b Mean of three determinations + S.D.

604

605

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

606
607
608
609

Table 2. Comparison of IgG anti-*T. canis* antibody concentration in human serum samples by microfluidic electrochemical immunosensor, microfluidic fluorescent immunosensor and ELISA.

Samples ^a	MEI ^b	MFI ^c	ELISA
1	1.05 + 0.01 ^d	1.07 + 0.02	0.93 + 0.03
5	4.95 + 0.06	4.91 + 0.06	5.13 + 0.05
10	10.14 + 0.05	10.16 + 0.04	9.88 + 0.06
25	25.19 + 0.08	24.79 + 0.09	25.23 + 0.08
50	49.13 + 0.10	49.23 + 0.12	50.47 + 0.14
70	70.53 + 0.15	69.41 + 0.17	69.33 + 0.18

610 ^a Human serum samples ng mL⁻¹ IgG anti-*T. canis* antibody.
611 ^b Microfluidic electrochemical immunosensor.
612 ^c Microfluidic fluorescent immunosensor.
613 ^d Mean of three determinations + S.D.
614

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: